Yaz Users File Lawsuits after Developing Deep Vein Thrombosis


Yaz Users File Lawsuits after Developing Deep Vein ThrombosisOverview: Parker Waichman LLP has filed lawsuits on behalf of two women who allegedly developed deep vein thrombosis (DVT) as a result of taking Yaz/Yasmin/Ocella. Bayer faces thousands of lawsuits claiming that the combination oral contraceptives cause blood clots and thrombotic events.

Product: Yaz, Yasmin (Drospirenone and Ethinyl Estradiol)

Manufacturer: Bayer AG





Side Effects & Complications

  • Blood Clots
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Gallbladder Damage
  • Heart Attacks
  • Stroke

The Lawsuit

The suits, filed on behalf of a Texas woman (Case No. 3:12-cv-10934-DRH-PMF) and a Massachusetts woman (Case No. 3:12-cv-10935-DRH-PMF) were transferred to the multidistrict litigation on May 29th (MDL No. 2100). Proceedings will take place in the U.S. District Court for the Southern District of Illinois before Judge David R. Herndon. According to a press release by Parker Waichman, the women allegedly developed deep vein thrombosis as a result of taking Yaz, its predecessor Yasmin or the generic Ocella. The complaints also claim severe and permanent personal injuries, pain, suffering, emotional distress, mental anguish, diminished enjoyment of life, and a future of high risk pregnancies.

The two women are among many suing Bayer over the effects of Yaz and Yasmin. According to the company’s 2011 annual report, there are over 11,300 product liability claims. In February, Bayer settled 70 lawsuits for an undisclosed amount. In April, the company agreed to settle another 500 lawsuits for $110 million.


Yaz, Yasmin and Ocella are combination oral contraceptives that contain drospirenone and ethinyl estradiol. Yasmin was first approved in 2001, while Yaz gained clearance in 2006. Drospirenone is a synthetic progesterone that is associated with an increased risk of blood clots. In April, the U.S. Food and Drug Administration (FDA) warned that the risk may be three times as likely in women who used contraceptives with drospirenone.